GAVI’S SUPPORT FOR IPV FOR INDIA (2019-2021)

BOARD MEETING
Hind Khatib-Othman
28-29 November 2018, Geneva
Partnership context and special circumstances surrounding the IPV request (2019-2021)

**Gavi / Global community**
- GPEI: catalytic IPV support
- Gavi: catalytic new vaccines and HSS support

**India** (eligible country)
- Champion for immunisation; model transitioning country
- Self-financing IPV for global good
- Dose sparing with fIPV
- Procurement savings contribution (>390M*)

- Funding request to bear unforeseen cost increase
- Cost-sharing (est. $40M for Gavi, for 50% cost-sharing for 3 years)

*Savings to Gavi and other countries to date, from pentavalent vaccine (2017-19) and PCV vaccine (AMC supply agreement)*
PPC considerations

• **Majority voted to recommend approval for the 3-year cost-sharing support**
  • High risk of poliovirus re-emergence in India and **risk to the global endgame strategy**
  • **Global market issues** impacting India’s trade-off decisions
  • **India’s global contribution**: IPV adoption and dose sparing, procurement savings to Gavi
  • **Gavi-India partnership risks**
  • **Equity considerations**: alignment with approach to IPV support for other eligible countries

• **Dissenting views**
  • Government of India’s **financial capacity** to absorb the incremental costs
  • Other alternative support mechanisms if available
  • Policy implications if setting a precedent
Recommendation

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

**Approve**, further to its decision on exceptional Gavi support for IPV from 2013 for Gavi eligible and graduating countries and the risks to the polio eradication agenda, the use of core resources (in an amount estimated at US$ 40 million based on current projections) to support inactivated poliovirus vaccine (IPV) in India for the period 2019-2021.
THANK YOU